Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $42.2 million.

  • Aytu Biopharma's Total Non-Current Liabilities rose 9723.55% to $42.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.2 million, marking a year-over-year increase of 9723.55%. This contributed to the annual value of $42.1 million for FY2025, which is 4971.76% up from last year.
  • Latest data reveals that Aytu Biopharma reported Total Non-Current Liabilities of $42.2 million as of Q4 2025, which was up 9723.55% from $35.8 million recorded in Q3 2025.
  • Aytu Biopharma's Total Non-Current Liabilities' 5-year high stood at $111.5 million during Q1 2021, with a 5-year trough of $14.4 million in Q1 2024.
  • Over the past 5 years, Aytu Biopharma's median Total Non-Current Liabilities value was $61.4 million (recorded in 2022), while the average stood at $63.8 million.
  • In the last 5 years, Aytu Biopharma's Total Non-Current Liabilities skyrocketed by 19088.24% in 2021 and then crashed by 8536.65% in 2024.
  • Aytu Biopharma's Total Non-Current Liabilities (Quarter) stood at $110.0 million in 2021, then dropped by 21.96% to $85.8 million in 2022, then tumbled by 60.15% to $34.2 million in 2023, then plummeted by 37.4% to $21.4 million in 2024, then skyrocketed by 97.24% to $42.2 million in 2025.
  • Its Total Non-Current Liabilities was $42.2 million in Q4 2025, compared to $35.8 million in Q3 2025 and $42.1 million in Q2 2025.